Wednesday, 25 Apr 2018

You are here

Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis

In this era of treat-to-target or remission targeted therapeutics, the options in managing nonresponders are many; often including off-label doses (i.e., dose escalations or reduction, increasing frequency; interrupted treatment). The use of above-label dosing, and its' effect on drug costs, has seldom been studied. 

Schwartzman and colleagues have studied biologic utilization in psoriatic arthritis (PsA), and the economic impact of increased doses, specifically looking at costs associated with above-label dosing and noncompliance with biologics in PsA.

Using MarketScan claims data they analyzed the first biologic claim with a 1-year follow-up period. The duration of use was stratified into three groups: <30, 30–179, and ≥180 days and defined above-label dosing as >10% of the labeled dose. They analyzed 4245 PsA patients treated with common biolgics (etanercept; n = 2342 ; adalimumab 1788, golimumab 115) between 2011 - 2013.

Above-label dosing for  <30 days was common and seen in 85% of adalimumab, 90.4% of etanercept, and 95.7% of golimumab patients. Longer term (≥180 days) was less common  (9.6% adalimumab, 4.1% etanercept, and 2.6% golimumab).

The mean number of days of on-label use ranged from 267 (adalimumab) to 295 (golimumab).

The mean number of days of above-label use was lowest with golimumab (12 days) and highest with adalimumab (35 days). Etanercept days of above-label use was 17  days.

Noncompliance could be inferred by no-use or below-label use days.  Below-label use was onlyreported for etanercept (4days) and adalimumab (1 day). No use was significantly higher for etanercept (71 days), compared to adalimumab (63 days), and golimumab (59 days).

All-cause total healthcare costs rose substantially with above-label use (p < 0.05).

These analyses suggest noncompliance with biologics is very common and that above-label use of anti-TNF biologics not only occurs, but is associated with significantly increased healthcare costs.

The clinical consequences or associations of these off-label dosing practices could not be studied in this claims dataset.

Dr. Schwartman collaborated with Novartis to perform these studies.

 

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Apremilast in DMARD-Naive Psoriatic Arthritis

Apremilast (Otezla) monotherapy was effective for psoriatic arthritis among patients who had not previously received disease-modifying anti-rheumatic drugs (DMARDs) or biologics, a phase III clinical trial funded by the drug's manufacturer found. 

Bone Marrow Edema Found in SI Joint of Athletes

New research shows that young elite athletes will not commonly manifest bone marrow edema in the SI joint following activity.

A study in Arthritis & Rheumatology  assessed for MRI findings commonly seen in patients with axial spondyloarthropathy (axial Spa). (Citation source: https://buff.ly/2DrlCgB)

Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis

Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.

Opioid Use in Ankylosing Spondylitis

A prospective study has shown that ankylosing spondylitis (AS) patients often require narcotic analgesics to manage pain unresponsive to antiinflammatory therapies.

AS patients (n=706) were serially assessed (every 6 months) and outcome measures were collected, including disease activity and functional measures (BASDAI, BASFI), along with radiographic outcomes.  Investigators specifically looked at opioid usage.

Cimzia Limits Xray Progression in Axial Spondyloarthritis

The RAPID-axSpA study of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients showed that certolizumab pegol (CZP) treatment yielded rapid clinical improvement with limited radiographic progression and MRI inflammation at the sacroiliiac (SI) joint over 4 years.